<abstract xmlns="http://www.w3.org/1999/xhtml"><p> Stavudine is a nucleoside analogue used widely for first-line treatment of HIV in developing and middleincome countries. The World Health Organization recommended that all patients should switch to stavudine (30mg BID). However, there is evidence from the dose-ranging trials that patients with body weight below 60kg should use a dose of 20mg BID. For patients who show adverse events on stavudine, a switch to other nucleoside analogues can be considered. This article reviews d4T to study if it should be kept or abandoned.</p></abstract>

Stavudine is a nucleoside analogue used widely for first-line treatment of HIV in developing and middleincome countries. The World Health Organization recommended that all patients should switch to stavudine (30mg BID). However, there is evidence from the dose-ranging trials that patients with body weight below 60kg should use a dose of 20mg BID. For patients who show adverse events on stavudine, a switch to other nucleoside analogues can be considered. This article reviews d4T to study if it should be kept or abandoned.

d4T: keep it or abandon it?

Asian Biomedicine

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

{"article-title":"d4T: keep it or abandon it?"}

Stavudine is a nucleoside analogue used widely for first-line treatment of HIV in developing and middleincome countries. The World Health Organization...

d4T: keep it or abandon it?

Online veröffentlicht: 13. Apr. 2018

Seitenbereich: 541 - 546

DOI: https://doi.org/10.2478/abm-2010-0068

Schlüsselwörter
Dose reduction, resource limited setting, stavudine

© 2018

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

d4T: keep it or abandon it?

Online veröffentlicht: 13. Apr. 2018

Seitenbereich: 541 - 546

DOI: https://doi.org/10.2478/abm-2010-0068

SchlüsselwörterDose reduction, resource limited setting, stavudine

© 2018

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Schlüsselwörter
Dose reduction, resource limited setting, stavudine